Arrhythmias & electrophysiology
Biomarkers to predict improvement of left ventricular ejection fraction after atrial fibrillation ablation
Authors' conclusion
A biomarker panel (ANG2 and GDF15) significantly improved the accuracy of the Antwerp score.
Study context
- Population
- Patients undergoing catheter ablation for atrial fibrillation (AF) with depressed left ventricular ejection fraction (LVEF) (<50%)
- Participants
- 208 patients
- Comparison
- Biomarker panel added to Antwerp score vs Antwerp score alone
- Respondersn = 161
- Nonrespondersn = 47reference
- Outcome
- LVEF recovery (responder) after CA
- Follow-up
- Median 30 (20-34) months
Methodological details13 plasma biomarkers measured immediately before catheter ablation (CA)
- 13 plasma biomarkers measured immediately before CA
Performance
As reported in the abstract
Prediction of LVEF recovery
- ANG2, GDF15, FGF23 and myosin binding protein C3 differed between responders and nonresponders
- P ≤ 0.001
- 4-biomarker combination AUC overall
- 0.72 (95% CI 0.64-0.81)
- 4-biomarker combination AUC in HF with mildly reduced EF
- 0.69 (95% CI 0.59-0.78)
- 4-biomarker combination AUC in HFrEF
- 0.88 (95% CI 0.77-0.98)
- ANG2 and GDF15 improved accuracy of Antwerp score
- P < 0.001
- Antwerp score AUC alone
- 0.75 (95% CI 0.67-0.83)
- Antwerp score + ANG2/GDF15 AUC
- 0.78 (95% CI 0.70-0.86)
Original publication
Biomarkers to predict improvement of left ventricular ejection fraction after atrial fibrillation ablation. Heart Rhythm. Published 11 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →